Chronic Myeloid Leukemia – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of CML for each country as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the developed world.

DRG Epidemiology’s CML forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with CML per year?
  • How will improvements in survival change the number of people diagnosed with CML per year?
  • Of all people diagnosed with CML, how many in each country across the world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CML over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but they may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following CML patient populations:

  • CML diagnosed incident cases.
  • CML diagnosed incident cases by phase distribution.
  • CML diagnosed prevalent cases.
  • CML progression events.
  • CML drug-treated subpopulation(s).

launch Related Market Assessment Reports